Xenon Pharmaceuticals Inc. company info

CIK 1582313
IRS Number 980661854
State of incorporation A1
Business address 200 - 3650 GILMORE WAY
V5G 48W
Mail address 200 - 3650 GILMORE WAY
V5G 48W

Short summary

Xenon Pharmaceuticals Inc. is a British Columbia, Canada company, with head office located at 200 - 3650 Gilmore Way Burnaby, British Columbia, Canada V5G 48W. In 2018 the company owned a total of 122.43 million USD worth of assets, including 121.44 million USD worth of current assets. The company amassed the most assets last year, totalling up to 122.43 million USD.

Xenon Pharmaceuticals Inc. Income Statement

Name [in Millions USD]20112012201320142015201620172018Trends
Research and development 10.4612.3011.7715.1519.8325.5723.63
Operating Expenses 17.4617.6417.2624.9426.6232.8938.02
Operating Income (Loss) -3.159.7111.11-9.36-24.82-32.58-38.02
Interest expense
Income Tax Expense (Benefit) 000
Net income -4.3012.0313.02-15.75-23.00-30.70-34.50

Xenon Pharmaceuticals Inc. Balance Sheet

Name [in Millions USD]20112012201320142015201620172018Trends
Cash and cash equivalents 13.9360.1635.0964.3535.2123.0947.4467.75
Accounts Receivable, Net, Current 0.440.190.660.200.170.26
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 14.1513.5414.5815.0815.6416.20
Total assets 54.4976.5355.6954.2365.44122.43
Current assets 49.8774.3553.3952.6364.35121.44
Total current liabilities 18.2012.022.933.523.094.12
Long-term Debt, Excluding Current Maturities 11.7215.01
Deferred Revenue, Noncurrent 11.890.16
Total liabilities 30.3712.183.033.7714.8219.13
Common Stock, Value, Issued 6.15147.82148.87173.84177.01265.92
Retained Earnings (Accumulated Deficit) -116.75-111.80-128.97-157.58-184.94-207.89
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.51-0.99-0.99-0.99-0.99-0.99

Xenon Pharmaceuticals Inc. Cash Flow

Name [in Millions USD]20112012201320142015201620172018Trends
Net income -4.3012.0313.02-15.75-23.00-30.70-34.50
Depreciation and amortization 0.790.710.741.040.860.650.59
Depreciation and amortization 0.790.710.74
Accounts receivable -11.230.08-0.210.11-0.120.23-0.18
Deferred revenue 35.49-16.36-14.41-11.62-0.16
Net Cash Provided by (Used in) Operating Activities -28.73-34.72
Payments to Acquire Property, Plant, and Equipment 0.530.161.530.550.280.320.51
Net Cash Provided by (Used in) Investing Activities 24.29-28.99
Net Cash Provided by (Used in) Investing Activities, Continuing Operations 0.49-11.47-3.2410.19-47.8424.29
Proceeds from Issuance of Common Stock 0.0542.640.2823.83102.85
Net Cash Provided by (Used in) Financing Activities 7.07111.59
Cash and Cash Equivalents, Period Increase (Decrease) 46.23-22.2134.08-13.38-41.563.3947.27